GILD250509C106000
- 0.23
- +0.20+666.67%
Gilead Sciences Newsroom
Express News | Gilead Sciences Inc - Stockholders Reject Dei Practices Risk Report Proposal for Contractors - SEC Filing
FDA to Speed up AI Rollout to Accelerate Drug Reviews
Merck Boosts U.S. Investments With $895M Expansion in Kansas Site
How To Put $100 In Your Retirement Fund Each Month With Gilead Sciences Stock
Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought
Gilead to Invest $11 Billion to Bolster Domestic Manufacturing and Research -- WSJ
Gilead Sciences | 10-Q: Quarterly report
Express News | Gilead to Invest $32 Billion in U.S. Manufacturing and R&D Through 2030 and Create More Than 3,000 Direct and Indirect Jobs by 2028
Gilead Sciences (NasdaqGS:GILD) Presents Promising Data On Livdelzi And Bulevirtide At EASL 2025
Express News | Gilead Showcases Livdelzi's Efficacy And Tolerability In PBC, With 60% Response Rate Among Patients With Prior Fibrate Or OCA Use, At EASL 2025
Express News | Gilead's Bulevirtide Shows Durability In Chronic HDV, With 90% of Patients on Long-Term Therapy Maintaining Undetectable HDV RNA Off-Treatment
Trump wants to impose tariffs on Pharmaceuticals: Pharmaceutical companies are busy stockpiling, and the import volume in the USA surged in March.
① The volume of Pharmaceutical imports in the USA surged in March, as pharmaceutical companies stockpiled products in anticipation of potential tariffs; ② A report released by the US Department of Commerce on Tuesday showed that the total value of Pharmaceutical imports in March exceeded 50 billion USD, equivalent to 20% of the total Pharmaceutical imports for the entire year of 2024.
Moderna, Pharma Stocks Fall as FDA Names Industry Critic as Top Vaccine Regulator
Gilead Sciences Down Nearly 5%, On Track for Largest Percent Decrease Since January 2024 -- Data Talk
Unusual Options Activity: SN, GILD and Others Attract Market Bets, SN V/OI Ratio Reaches 253.5
TD Cowen Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $110
TD Cowen Keeps Their Buy Rating on Gilead Sciences (GILD)
Argus Research Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $120
These Are the Sectors Best Liked Within Defensive and Cyclicals Groups – Morgan Stanley
Express News | Gilead : Mizuho Raises Target Price to $117 From $100